TY - JOUR
T1 - Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents
T2 - A multiregional analysis from Southern Africa, West Africa and Europe
AU - Schomaker, Michael
AU - Leroy, Valeriane
AU - Wolfs, Tom
AU - Technau, Karl-Günter
AU - Renner, Lorna
AU - Judd, Ali
AU - Sawry, Shobna
AU - Amorissani-Folquet, Madeleine
AU - Noguera-Julian, Antoni
AU - Tanser, Frank
AU - Eboua, Frančois
AU - Navarro, Maria Luisa
AU - Chimbetete, Cleophas
AU - Amani-Bosse, Clarisse
AU - Warszawski, Josiane
AU - Phiri, Sam
AU - N'Gbeche, Sylvie
AU - Cox, Vivian
AU - Koueta, Fla
AU - Giddy, Janet
AU - Sygnaté-Sy, Haby
AU - Raben, Dorthe
AU - Chêne, Geneviève
AU - Davies, Mary-Ann
N1 - Publisher Copyright:
© The Author 2016; all rights reserved.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Background: There is limited knowledge about the optimal timing of antiretroviral treatment initiation in older children and adolescents. Methods: A total of 20 576 antiretroviral treatment (ART)-naïve patients, aged 1-16 years at enrolment, from 19 cohorts in Europe, Southern Africa and West Africa, were included. We compared mortality and growth outcomes for different ART initiation criteria, aligned with previous and recent World Health Organization criteria, for 5 years of follow-up, adjusting for all measured baseline and time-dependent confounders using the g-formula. Results: Median (1st;3rd percentile) CD4 count at baseline was 676 cells/mm3 (394; 1037) (children aged ≥ 1 and < 5 years), 373 (172; 630) (≥ 5 and < 10 years) and 238 (88; 425) (≥ 10 and < 16 years). There was a general trend towards lower mortality and better growth with earlier treatment initiation. In children < 10 years old at enrolment, by 5 years of follow-up there was lower mortality and a higher mean height-for-age z-score with immediate ART initiation versus delaying until CD4 count < 350 cells/mm3 (or CD4% < 15% or weight-for-age z-score < -2) with absolute differences in mortality and heightfor- age z-score of 0.3% (95% confidence interval: 0.1%; 0.6%) and -0.08 (-0.09; -0.06) (≥ 1 and < 5 years), and 0.3% (0.04%; 0.5%) and -0.07 (-0.08; -0.05) (≥ 5 and < 10 years). In those aged > 10 years at enrolment we did not find any difference in mortality or growth with immediate ART initiation, with estimated differences of -0.1% (-0.2%; 0.6%) and - 0.03 (-0.05; 0.00), respectively. Growth differences in children aged < 10 years persisted for treatment thresholds using higher CD4 values. Regular follow-up led to better height and mortality outcomes. Conclusions: Immediate ART is associated with lower mortality and better growth for up to 5 years in children < 10 years old. Our results on adolescents were inconclusive.
AB - Background: There is limited knowledge about the optimal timing of antiretroviral treatment initiation in older children and adolescents. Methods: A total of 20 576 antiretroviral treatment (ART)-naïve patients, aged 1-16 years at enrolment, from 19 cohorts in Europe, Southern Africa and West Africa, were included. We compared mortality and growth outcomes for different ART initiation criteria, aligned with previous and recent World Health Organization criteria, for 5 years of follow-up, adjusting for all measured baseline and time-dependent confounders using the g-formula. Results: Median (1st;3rd percentile) CD4 count at baseline was 676 cells/mm3 (394; 1037) (children aged ≥ 1 and < 5 years), 373 (172; 630) (≥ 5 and < 10 years) and 238 (88; 425) (≥ 10 and < 16 years). There was a general trend towards lower mortality and better growth with earlier treatment initiation. In children < 10 years old at enrolment, by 5 years of follow-up there was lower mortality and a higher mean height-for-age z-score with immediate ART initiation versus delaying until CD4 count < 350 cells/mm3 (or CD4% < 15% or weight-for-age z-score < -2) with absolute differences in mortality and heightfor- age z-score of 0.3% (95% confidence interval: 0.1%; 0.6%) and -0.08 (-0.09; -0.06) (≥ 1 and < 5 years), and 0.3% (0.04%; 0.5%) and -0.07 (-0.08; -0.05) (≥ 5 and < 10 years). In those aged > 10 years at enrolment we did not find any difference in mortality or growth with immediate ART initiation, with estimated differences of -0.1% (-0.2%; 0.6%) and - 0.03 (-0.05; 0.00), respectively. Growth differences in children aged < 10 years persisted for treatment thresholds using higher CD4 values. Regular follow-up led to better height and mortality outcomes. Conclusions: Immediate ART is associated with lower mortality and better growth for up to 5 years in children < 10 years old. Our results on adolescents were inconclusive.
KW - Antiretroviral treatment
KW - Causal inference
KW - G-formula
KW - Paediatrics
UR - http://www.scopus.com/inward/record.url?scp=85028696291&partnerID=8YFLogxK
U2 - 10.1093/ije/dyw097
DO - 10.1093/ije/dyw097
M3 - Article
AN - SCOPUS:85028696291
SN - 0300-5771
VL - 46
SP - 453
EP - 465
JO - International Journal of Epidemiology
JF - International Journal of Epidemiology
IS - 2
ER -